EN
/
CN
home
about us
Company profile
Strategic layout
Contact Us
products
TCR-T cell therapy
TCR-fusion protein therapy
news
strength
Technology platform
Manufacturing process
responsibility
sevice
Clinical trials
Download Center
EN
/
CN
NEWS
HOME
NEWS
NEWS
ALL
2022
2021
2020
2019
2018
...
20
Aug.
2022
The 3rd QbD Summit in 2022 was successfully concluded
12
Aug.
2022
Stick to high quality·Aiming at internationalization|The 3rd Quality Science of Biologics Summit in 2022 was successfully concluded
02
Aug.
2022
CorreGene completed the pre-A round of financing of nearly 100 million yuan, and will be deeply committed to TCR innovative drug research and development
20
Aug.
2022
The 3rd QbD Summit in 2022 was successfully concluded
12
Aug.
2022
Stick to high quality·Aiming at internationalization|The 3rd Quality Science of Biologics Summit in 2022 was successfully concluded
02
Aug.
2022
CorreGene completed the pre-A round of financing of nearly 100 million yuan, and will be deeply committed to TCR innovative drug research and development
20
Aug.
2022
The 3rd QbD Summit in 2022 was successfully concluded
12
Aug.
2022
Stick to high quality·Aiming at internationalization|The 3rd Quality Science of Biologics Summit in 2022 was successfully concluded
1
2
3
...
10